Vascular wall ACE is not required for atherogenesis in ApoE-/- mice

Atherosclerosis

Volumn 209, Issue 2, 2010, Pages 352-358

  Weiss, Daiana ^a   Bernstein, Kenneth E ^a,c   Fuchs, Sebastian ^a,c   Adams, Jonathan ^a   Synetos, Andreas ^a   Taylor, W Robert ^a,b,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Emory University   (United States)

Author keywords

Angiotensin; Atherosclerosis; Endothelium

Indexed keywords

APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD VESSELS; MALE; MICE; MICE, KNOCKOUT; PEPTIDYL-DIPEPTIDASE A;

EID: 77950022915     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.069     Document Type: Article

References (37)

1. Daugherty A., Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 2004, 14(3):117-120.
2. Dzau V.J. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37(4):1047-1052.
3. Gibbons G.H. The pathophysiology of hypertension: the importance of angiotensin II in cardiovascular remodeling. Am J Hypertens 1998, 11(11 Pt 2):177S-181S.
4. Griendling K.K., Ushio-Fukai M. Reactive oxygen species as mediators of angiotensin II signaling. Regul Pept 2000, 91(1-3):21-27.
5. Griendling K.K., Ushio-Fukai M., Lassegue B., Alexander R.W. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997, 29(1 Pt 2):366-373.
6. Weiss D., Sorescu D., Taylor W.R. Angiotensin II and atherosclerosis. Am J Cardiol 2001, 87(8A):25C-32C.
7. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88(Suppl. 9):1L-20L.
8. Lee M.A., Bohm M., Paul M., Ganten D. Tissue renin-angiotensin systems. Their role in cardiovascular disease. Circulation 1993, 87(Suppl. 5):IV7-13.
9. Potter D.D., Sobey C.G., Tompkins P.K., Rossen J.D., Heistad D.D. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998, 98(8):800-807.
10. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999, 17(4):537-545.
11. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996, 94(11):2756-2767.
12. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002, 16(2):149-160.
13. Schiffrin E.L. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens 2002, 15(10 Pt 2):115S-122S.
14. Esther C.R., Marino E.M., Howard T.E., Machaud A., Corvol P., Capecchi M.R., et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997, 99(10):2375-2385.
15. Shen X.Z., Xiao H.D., Li P., Lin C.X., Billet S., Okwan-Duodu D., et al. New insights into the role of angiotensin-converting enzyme obtained from the analysis of genetically modified mice. J Mol Med 2008, 86(6):679-684.
16. Cole J., Quach D.L., Sundaram K., Corvol P., Capecchi M.R., Bernstein K.E. Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res 2002, 90(1):87-92.
17. Esther C.R., Howard T.E., Marino E.M., Goddard J.M., Capecchi M.R., Bernstein K.E. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996, 74(5):953-965.
18. Weiss D., Kools J.J., Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 103(3):448-454.
19. Cole J.M., Khokhlova N., Sutliff R.L., Adams J.W., Disher K.M., Zhao H., et al. Mice lacking endothelial ACE: normal blood pressure with elevated angiotensin II. Hypertension 2003, 41(2):313-321.
20. Kon V., Jabs K. Angiotensin in atherosclerosis. Curr Opin Nephrol Hypertens 2004, 13(3):291-297.
21. Ferrario C.M., Richmond R.S., Smith R., Levy P., Strawn W.B., Kivlighn S. Renin-angiotensin system as a therapeutic target in managing atherosclerosis. Am J Ther 2004, 11(1):44-53.
22. Kowala M.C., Grove R.I., Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994, 108(1):61-72.
23. Hope S., Brecher P., Chobanian A.V. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999, 12(1 Pt 1):28-34.
24. Hayek T., Attias J., Coleman R., Brodsky S., Smith J., Breslow J.L., et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999, 44(3):579-587.
25. Sun Y.P., Zhu B.Q., Browne A.E., Pulukurthy S., Chou T.M., Sudhir K., et al. Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J Cardiovasc Pharmacol Ther 2001, 6(2):175-181.
26. Candido R., Jandeleit-Dahm K.A., Cao Z., Nesteroff S.P., Burns W.C., Twigg S.M., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002, 106(2):246-253.
27. Schuh J.R., Blehm D.J., Frierdich G.E., McMahon E.G., Blaine E.H. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 1993, 91(4):1453-1458.
28. Keidar S., Attias J., Coleman R., Wirth K., Scholkens B., Hayek T. Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol 2000, 35(1):64-72.
29. Hayek T., Attias J., Smith J., Breslow J.L., Keidar S. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 1998, 31(4):540-544.
30. da Cunha V., Tham D.M., Martin-McNulty B., Deng G., Ho J.J., Wilson D.W., et al. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005, 178(1):9-17.
31. Wassmann S., Czech T., van Eickels M., Fleming I., Bohm M., Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 2004, 110(19):3062-3067.
32. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105(11):1605-1612.
33. Daugherty A., Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice. Ann N Y Acad Sci 1999, 892:108-118.
34. Hayek T., Pavlotzky E., Hamoud S., Coleman R., Keidar S., Aviram M., et al. Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2. Arteriosc Thromb Vasc Biol 2003, 23(11):2090-2096.
35. Weiss D., Taylor W.R. Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II. Hypertension 2008, 51(2):218-224.
36. Petrov V., Fagard R., Lijnen P. Effect of protease inhibitors on angiotensin-converting enzyme activity in human T-lymphocytes. Am J Hypertens 2000, 13(5 Pt 1):535-539.
37. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118(3):984-93.